I n a turbulent market environment, SLRN stock has reached a 52-week low, trading at $1.85. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio ...

I n a year marked by significant volatility, SLRN stock has reached a new 52-week low, trading at $1.9. With a market capitalization of $196.64 million, the company maintains strong liquidity with ...

In this article, we are going to take a look at where Acelyrin, Inc. (NASDAQ:SLRN) stands against the other micro cap stocks. Just as we overlook loose change, micro-cap stocks are often ignored ...

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...

Acelyrin (NASDAQ:SLRN) traded sharply lower on Tuesday after the company and its California-based rival Alumis (NASDAQ:ALMS) reaffirmed their commitment to merge in line with their previously ...

Acelyrin (NASDAQ:SLRN) announced Thursday a decision to adopt a limited-duration stockholder rights plan, also known as a poison pill, after Tang Capital Partners rapidly accumulated 8.8% of the ...

(NASDAQ: SLRN) to Alumis Inc. for 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock is fair to ACELYRIN shareholders. Halper Sadeh encourages ACELYRIN shareholders to ...

We recently compiled a list of the 10 Best Micro Cap Stocks to Buy Now. In this article, we are going to take a look at where Acelyrin, Inc. (NASDAQ:SLRN) stands against the other micro cap stocks.

Alumis (ALMS) and ACELYRIN (SLRN) reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases.